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Abstract We examined the e¡ect of sodium butyrate on in
vitro angiogenesis and cyclooxygenase (COX) expression using
primary cultures of human intestinal microvascular endothelial
cells (HIMEC). Butyrate inhibited VEGF-induced cellular pro-
liferation, transmigration and tube formation of HIMEC. Bu-
tyrate also inhibited COX-2 expression as well as prostaglandin
(PG)E2 and PGI2 production, and administration of PGI2 ana-
log partially reversed the e¡ect of butyrate on HIMEC angio-
genesis. These results indicate that sodium butyrate inhibits
HIMEC angiogenesis through down-regulation of COX-2 ex-
pression and PG production, and suggest that anti-angiogenic
mechanisms may also be involved in the inhibitory e¡ect of
sodium butyrate on tumor growth.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Sodium butyrate, a short-chain fatty acid (SCFA) produced
during colonic microbial ¢ber fermentation, is currently being
evaluated as an anti-neoplastic therapeutic [1], and clinical
trials of butyrate and its derivatives in cancer patients have
already been initiated [2,3]. The preventive action of butyrate
against tumor growth is believed to be mediated through a
direct e¡ect on tumor cells which results in cell cycle arrest,
di¡erentiation or apoptosis [4^7]. However, the e¡ect of so-
dium butyrate on microvascular endothelial cells, which play
a key role in tumor-induced angiogenesis, is presently not
de¢ned. In the present study, we examined the e¡ect of so-
dium butyrate on in vitro angiogenesis using primary cultures
of human intestinal microvascular endothelial cells (HIMEC).
Sodium butyrate demonstrated a potent anti-angiogenic e¡ect
on HIMEC as well as inhibitory e¡ects on cyclooxygenase-2
(COX-2) expression and prostanoid production. The COX-2-
speci¢c inhibitor NS398 impaired in vitro angiogenesis of HI-
MEC, suggesting that the anti-angiogenic mechanism of bu-
tyrate was related to this enzyme. Administration of exoge-
nous prostaglandin (PG)I2 analog reversed the inhibitory
e¡ect of sodium butyrate on HIMEC. These ¢ndings suggest
that in addition to e¡ects on epithelial cells, sodium butyrate
is a potent anti-angiogenic agent.
2. Materials and methods
2.1. Western blotting for COX-1 and COX-2
HIMEC isolation was performed from normal-appearing small or
large bowel mucosa as described previously [8] and pure HIMEC
monolayers were cultured in media containing 5% fetal bovine serum
(FBS) overnight prior to assay. Con£uent HIMEC monolayers were
assessed directly or following stimulation with vascular endothelial
growth factor (VEGF; RpD systems, Minneapolis, MN, USA;
50 ng/ml, 4 h) with or without sodium butyrate pre-treatment (Sigma
Chemical, St. Louis, MO, USA; 0.05^5 mM, 2 h). Cellular protein
was extracted as described previously [8], and 10 Wg of protein was
applied for Western blot analysis with anti-COX-1, -2 monoclonal
antibodies or anti-actin goat polyclonal antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Following incubation with sec-
ondary horseradish peroxydase (HRP)-conjugated anti-mouse or
-goat IgG (Santa Cruz Biotechnology), bands were detected using
enhanced chemiluminescence (ECL) reagents (Amersham Bioscience,
Piscataway, NJ, USA), according to the manufacturer’s protocol.
For statistical analysis, ¢lms were scanned and the intensity of each
band was determined using the public domain NIH Image program
(developed at the U.S. National Institutes of Health and available on
the Internet at http://rsb.info.nih.gov/nih-image/). The relative ratio of
COX-2/COX-1 expression was determined as [COX-2/COX-1 in each
group]/[COX-2/COX-1 in HIMEC with no stimulation]. Experiments
were carried out using three independent HIMEC cultures and results
are expressed as meanIS.E.M.
2.2. Determination of PGE2 and 6-keto PGF1K concentration in culture
supernatant
Con£uent HIMEC monolayers were assayed directly or following
VEGF stimulation (50 ng/ml, 8 h) with sodium butyrate pre-treatment
(0^5 mM, 2 h). The concentration of PGE2 and 6-keto PGF1K (the
stable metabolite of PGI2) in the culture supernatant was determined
using a commercial enzyme immunoassay (Cayman Chemical, Ann
Arbor, MI, USA). In order to determine the COX isozyme which
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produces PGE2 and PGI2 in HIMEC, the monolayers were incubated
with the COX-2-speci¢c inhibitor NS398 for 2 h (0.05^5 WM; Cayman
Chemical) and stimulated with VEGF for 8 h. The concentration of
PGE2 and 6-keto PGF1K was determined as described above. Experi-
ments were carried out in triplicate and results are shown as mean pg/
ml I S.D.
2.3. Thymidine incorporation assay
Cellular DNA synthesis was assessed by [3H]thymidine uptake. HI-
MEC were seeded onto ¢bronectin-coated 24-well plates (1.5U104
cells/cm2) and grown for 24 h. After incubation in media containing
1% FBS overnight, cells were treated with sodium butyrate (0^5 mM)
for 2 h, and stimulated with VEGF (50 ng/ml). When indicated, PGE2
(11-deoxy Prostaglandin E2; Cayman Chemical), carbacyclin (stable
analog of PGI2 ; Cayman Chemical) or U46619 (thromboxane A2
(TXA2) receptor agonist; Cayman Chemical) were added to the media
at either 0.1 or 1 WM. Following 15 h of stimulation, [3H]thymidine
(1 WCi/ml; Amersham Biosciences) was added to media and cells were
cultured another 5 h. After washing twice with PBS, cells were ¢xed
for 10 min on ice with 5% (v/v) trichloroacetic acid. DNA was then
released from precipitated material by alkaline lysis in 0.25 N NaOH
and supernatants were quanti¢ed in a gamma counter. Data from
triplicate wells were expressed as a meanIS.D.
2.4. Quanti¢cation of cell number and viability
To determine the e¡ect of butyrate on cellular proliferation and
viability, sub-con£uent HIMEC monolayers in 1% FBS media were
treated with butyrate (0.5 or 5 mM) for 2 h and stimulated with
VEGF (50 ng/ml). After 18 h stimulation, cells were detached by
trypsin^EDTA treatment, and cell number and viability were quanti-
¢ed under a light microscope by trypan blue staining. Data from
triplicate wells were expressed as a relative ratio of cell number (%
of unstimulated cells) I S.D.
2.5. Endothelial cell chemotaxis assay
HIMEC (3U104 cells/cm2) were cultured on ¢bronectin-coated
polycarbonate ¢lters (8 Wm pore size, BD Biosciences, Bedford,
MA, USA). After incubation in media containing 2% FBS overnight,
HIMEC were incubated with butyrate (0^5 mM) or NS398 (0.05^0.5
WM) for 2 h, and bu¡ers containing VEGF (50 ng/ml) were ¢lled into
the lower compartment of the 12-well plates. When indicated, PGE2,
carbacyclin or U46619 were added into both upper and lower cham-
bers at either 0.1 or 1 WM. After overnight incubation, cell culture
inserts were removed and the upper surface of the membrane was
gently wiped to remove non-migrated cells. Filters were stained with
Di¡Quik (Baxter Scienti¢c, McGraw, IL, USA), air-dried, and
mounted onto glass slides. Migrated HIMEC adherent to the lower
side of the membrane were counted (at least 15 random high-power
¢elds (U200) per condition) and data were expressed as a meanIS.D.
2.6. In vitro tube formation assay
Endothelial tube formation was assessed using Matrigel1 (BD Bio-
sciences), a solubilized extracellular basement membrane matrix ex-
tracted from the Engelbreth^Holm^Swarm mouse sarcoma, as de-
scribed previously [9]. Multiwell dishes (24-well) were coated with
250 Wl of MCDB 131 medium containing 5 mg/ml Matrigel1 and
10% FBS. HIMEC were pre-treated with butyrate (0^5 mM) or
NS398 (0.05^2 WM) for 30 min, and were seeded at a density of
5U104 cells/well. The concentration of butyrate or NS398 was main-
tained in both the cell suspension and Matrigel1 during the assay.
When indicated, the medium was supplemented with PGE2, carbacy-
clin or U46619. Cells were cultured on Matrigel1 for 10^16 h and
endothelial tube formation was assessed by inverted phase-contrast
microscopy. At least 10 high-power ¢elds per condition were exam-
ined, and experiments were repeated in two independent HIMEC
cultures. Data were expressed as a mean number of tubes per high-
power ¢eld (U200)I S.D.
3. Results
3.1. Sodium butyrate inhibits COX-2 expression and prostanoid
production in HIMEC
HIMEC cultured in 5% FBS-containing media demon-
strated detectable COX-2 protein expression, which was sig-
ni¢cantly increased by VEGF stimulation for 4 h (Fig. 1A,B).
Pre-treatment with sodium butyrate inhibited COX-2 expres-
sion in a dose-dependent manner. In contrast, COX-1 expres-
sion was not a¡ected by VEGF or sodium butyrate. Corre-
sponding with the e¡ect on COX-2 expression, sodium
butyrate inhibited both PGE2 and PGI2 (determined as
6-keto PGF1K) production induced by VEGF (Fig. 1C). At
greater than 2 mM butyrate, both PG levels were less than the
basal production without VEGF stimulation. Both PGE2 and
PGI2 production are strongly inhibited by pre-treatment with
NS398 as low as 0.05 WM, indicating that production of these
prostanoids is largely dependent on COX-2 activity in HI-
MEC.
3.2. Sodium butyrate inhibits HIMEC proliferation, migration
and tube formation, which are partially reversed by PGI2
analog administration
Cellular proliferation was determined by measuring both
[3H]thymidine uptake and cell number. [3H]thymidine uptake
was signi¢cantly increased after VEGF stimulation, which was
inhibited by sodium butyrate pre-treatment in a dose-depen-
dent manner (Fig. 2A). VEGF stimulation for 18 h increased
the number of cells, although it was not statistically signi¢-
cant. Pre-treatment with 5 mM butyrate reduced cell number
signi¢cantly in VEGF-stimulated HIMEC (Fig. 2B). The
cellular viability remained over 98% in all groups (data
not shown). The inhibitory e¡ect of sodium butyrate on
HIMEC [3H]thymidine uptake was partially reversed by ad-
ministration of the PGI2 analog carbacyclin, but not by 11-de-
oxy PGE2 or U46619 (stable PGE2 or TXA2 analog, respec-
tively) (Fig. 2C).
HIMEC transmigration was also increased by VEGF stim-
ulation and was signi¢cantly inhibited by pre-treatment with
sodium butyrate (either 0.5 or 5 mM; Fig. 3A). Similar to the
results of the [3H]thymidine uptake assay, carbacyclin partial-
ly reversed the inhibitory e¡ect of sodium butyrate on HI-
MEC transmigration, but PGE2 or TXA2 analogs did not
exert an e¡ect (Fig. 3B).
The endothelial in vitro tube formation assay using Matri-
gel1 was performed in the absence of VEGF, because VEGF
stimulation did not signi¢cantly a¡ect microvascular tube for-
mation in our preliminary experiments (data not shown). Sim-
ilar to the results from the cell proliferation and transmigra-
tion assays described previously, the number of endothelial
tubes which formed in Matrigel1 was signi¢cantly inhibited
by sodium butyrate (2.5 mM). The inhibitory e¡ect of sodium
butyrate on endothelial tube formation was also partially re-
versed by the administration of carbacyclin, but not by 11-de-
oxy PGE2 or U46619 (Fig. 4).
3.3. The COX-2-speci¢c inhibitor NS398 inhibits HIMEC
transmigration and tube formation
In order to determine the causal relationship between inhi-
bition of COX-2 and inhibition of in vitro angiogenesis of
HIMEC, transmigration and tube formation assays were per-
formed using the COX-2 speci¢c inhibitor NS398. NS398 ex-
erts a potent e¡ect on HIMEC, inhibiting prostanoid produc-
tion as demonstrated above. As shown in Fig. 5, both
transmigration and tube formation were signi¢cantly inhibited
by NS398 in concentrations as low as 0.05 WM. These results
indicate that inhibition of COX-2 activity is linked to im-
paired HIMEC angiogenesis in vitro.
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4. Discussion
In the present study, our data demonstrate that (i) sodium
butyrate inhibited VEGF-induced proliferation, transmigra-
tion and tube formation in HIMEC, an in vitro strategy for
modeling angiogenesis, (ii) sodium butyrate blocked VEGF-
induced COX-2 expression as well as prostanoid production,
(iii) the administration of PGI2 analog carbacyclin partially
Fig. 1. E¡ect of sodium butyrate on COX protein expression and prostanoid production in HIMEC. A: The results of Western blotting for
COX-1 and COX-2. VEGF stimulation increased COX-2 expression, which was signi¢cantly inhibited by sodium butyrate. COX-1 expression
was not a¡ected by VEGF or sodium butyrate. Actin served as an internal control. Representative result from a total of three independent ex-
periments. B: The result of the statistical analysis for the relative ratio of COX-2/COX-1 expression. The intensity of each band was deter-
mined using image analysis software and the relative ratio of COX-2/COX-1 expression was determined as [COX-2/COX-1 in each group]/
[COX-2/COX-1 in HIMEC with no stimulation]. Experiments were carried out using three independent HIMEC cultures and results are ex-
pressed as meanIS.E.M. *=P6 0.05 compared to no stimulation; **=P6 0.05 compared to VEGF stimulation by analysis of variance (AN-
OVA). C: The results of enzyme immunoassay for PGE2 and 6-keto PGF1K in HIMEC culture supernatants. VEGF stimulation signi¢cantly
increased both PGE2 and 6-keto PGF1K production in HIMEC. Sodium butyrate inhibited production of both prostanoids in a dose-dependent
manner. Representative result from a total of three independent experiments. Data were expressed as pg/ml PG productionIS.D. *=P6 0.05
compared to no stimulation; **=P6 0.05 compared to VEGF stimulation by ANOVA. D: The results of enzyme immunoassay for PGE2 and
6-keto PGF1K with NS398 treatment. NS398 inhibited production of both prostanoids as low as 0.05 WM in HIMEC. *=P6 0.05 compared to
VEGF stimulation by ANOVA.
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reversed the inhibitory e¡ect of sodium butyrate on thymidine
uptake, transmigration and tube formation, and (iv) the
COX-2-speci¢c inhibitor NS398 also inhibits HIMEC trans-
migration and tube formation. These results suggest that so-
dium butyrate will inhibit microvascular endothelial growth
and proliferation and suppress angiogenesis by inhibiting
COX-2 expression and PG production. The inhibitory e¡ect
of sodium butyrate on [3H]thymidine uptake (Fig. 2A), trans-
migration (Fig. 3A), tube formation (Fig. 4D) as well as pros-
tanoid production (Fig. 1C) appears to be greater than an
e¡ect attributed to the reduction in endothelial cell numbers
caused by this SCFA (Fig. 2B). Thus these data suggest that
the inhibition of in vitro angiogenesis or reduced prostanoid
production is the result of speci¢c e¡ects of butyrate on
VEGF-induced activation in HIMEC.
Recent evidence demonstrates that VEGF induces COX-2
expression in endothelial cells and COX-derived prostanoids
promote angiogenesis in response to VEGF stimulation
[10,11]. Our present data also demonstrate that VEGF en-
hanced COX-2 protein expression in HIMEC. Furthermore,
we ¢rst demonstrated that COX-2 expression in HIMEC was
inhibited by sodium butyrate in a dose-dependent manner.
Sodium butyrate also blocked serum- or lipopolysaccharide
(LPS)-induced COX-2 expression in HIMEC (data not
shown), indicating that sodium butyrate is a potent inhibitor
of COX-2 expression as well as prostanoid production in en-
dothelial cells regardless of the type of stimuli. The suppressed
COX-2 expression is not likely to be the result of generalized
cellular unresponsiveness or damage, because sodium butyrate
at 0.5^5 mM did not a¡ect LPS-induced E-selectin expression
and in fact resulted in increased ICAM-1 expression [12].
Therefore, butyrate appears to alter HIMEC gene/protein ex-
pression in a gene-speci¢c manner. In addition, the inhibitory
e¡ect of butyrate on COX-2 expression seems to be speci¢c to
endothelial cells, because it did not a¡ect COX-2 expression in
smooth muscle cells isolated from intestinal mucosa (data not
shown), and a recent report has shown that butyrate increased
COX-2 expression in epithelial cells [13].
COX-2 and prostanoid have been implicated in mediating
angiogenesis during tumor growth. COX-2 is up-regulated in
the microvasculature surrounding colon tumors [14], and in-
hibition of COX activity by non-steroidal anti-in£ammatory
drugs (NSAIDs) reduces angiogenesis and tumor growth both
in vivo and in vitro [15,16]. Recent reports also indicate that
COX-2-derived PGE2, TXA2 or PGI2 promote angiogenesis
[10,15,17], although the predominant role of endothelial
COX-2 vs. COX-1 in angiogenesis remains controversial
[18]. In the present study, we demonstrate that the COX-2
inhibitor NS398 impaired in vitro angiogenesis of HIMEC,
supporting the idea that COX-2-derived prostanoids play a
Fig. 2. E¡ect of sodium butyrate on HIMEC proliferation. A: Cel-
lular DNA synthesis was assessed by measuring [3H]thymidine up-
take. [3H]thymidine uptake was signi¢cantly increased after VEGF
stimulation for 15 h and was inhibited by sodium butyrate pre-treat-
ment for 2 h in a dose-dependent manner. Assays were done in trip-
licate and the data are shown as mean cpmIS.D. Representative
results from a total of three independent experiments are shown.
*=P6 0.05 compared to VEGF-stimulated HIMEC cultures by
ANOVA. B: Number of HIMEC was counted after VEGF stimula-
tion with or without butyrate treatment. VEGF stimulation ap-
peared to increase the number of HIMEC after 18 h, but failed to
reach signi¢cance (Ps 0.05). Sodium butyrate at 5 mM signi¢cantly
decreased the number of cells compared to VEGF stimulation
alone. Data from triplicate wells were expressed as a relative ratio
of cell number (% of unstimulated cells) I S.D. Representative re-
sults from a total of two independent experiments are shown.
*=P6 0.05 compared to VEGF-stimulated HIMEC cultures by
ANOVA. C: The inhibitory e¡ect of sodium butyrate on
[3H]thymidine uptake was partially reversed by exogenous carbacy-
clin (PGI2 analog) administration, but not by 11-deoxy PGE2 or
U46619 (PGE2 or TXA2 analog, respectively). *=P6 0.05 com-
pared to sodium butyrate-treated HIMEC without exogenous PG
administration (lane 3) by ANOVA.
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central role in angiogenesis. The administration of PGI2 ana-
log carbacyclin reversed the inhibition of thymidine uptake,
transmigration and tube formation by sodium butyrate. Thus,
the e¡ect of sodium butyrate could be explained in part by
suppression of PGI2 formation through inhibition of COX-2
expression. No reversal of inhibition was observed by admin-
istration of PGE2 and TXA2 analogs, suggesting that among
the major COX products, loss of PGI2 underlies the e¡ect of
sodium butyrate on HIMEC angiogenesis. These results are
consistent with a recent report demonstrating that administra-
tion of PGI2 analog, but not PGE2 or TXA2 analogs, reversed
the e¡ect of COX-2 inhibitor on blocking endothelial cellular
proliferation [11]. However, it should be noted that PGI2
analog did not overcome the anti-angiogenic e¡ect of sodium
butyrate completely, and it appears that butyrate inhibits HI-
MEC angiogenesis more strongly than NS398. Conversely,
when we consider that NS398 inhibits prostanoid production
more e¡ectively than butyrate, the anti-angiogenic e¡ect of
this SCFA will involve mechanisms in addition to its inhibi-
tory e¡ect on COX-2 expression in HIMEC. In addition to
the e¡ect on COX-2 expression, sodium butyrate also a¡ects
expression of several genes associated with cell growth and/or
apoptosis (e.g. Bcl2 etc.; unpublished data), and a recent re-
port demonstrates that sodium butyrate inhibits endothelial
nitric oxide synthase (eNOS) expression in endothelial cells
which may contribute to impaired endothelial tube formation
[19]. Sodium butyrate’s e¡ects on gene expression are believed
to involve inhibition of histone deacetylase (HDAC), which
may result in either the expression or silencing of speci¢c
genes. Recent reports using human and animal large-vessel
endothelial cells have suggested that HDAC inhibitors are
potent anti-angiogenic agents in vitro and in vivo, through
Fig. 3. E¡ect of sodium butyrate on HIMEC transmigration. Endo-
thelial transmigration assay was performed using polycarbonate ¢l-
ters (8 Wm pore size). HIMEC which transmigrated through the ¢l-
ters to the lower side of the membrane were counted (at least 15
random high-power ¢elds (U200) per condition) and data were ex-
pressed as a meanIS.D. A: The number of transmigrated HIMEC
was increased by VEGF stimulation, which was signi¢cantly inhib-
ited by pre-treatment with sodium butyrate. Representative result
from a total of four independent experiments. * =P6 0.05 com-
pared to VEGF-stimulated HIMEC by ANOVA. B: The inhibitory
e¡ect of sodium butyrate on HIMEC transmigration was signi¢-
cantly reversed by carbacyclin administration at 1 WM. Representa-
tive result from a total of three independent experiments.
*=P6 0.05 compared to VEGF-stimulated HIMEC with butyrate
pre-treatment (lane 3) by ANOVA.
Fig. 4. E¡ect of sodium butyrate on in vitro tube formation of HI-
MEC. A: HIMEC cultured overnight on 5 mg/ml Matrigel1 form
microvascular tubes. Phase-contrast photomicrograph demonstrates
¢ne capillary-like structures which form a delicate lattice work over
the tissue culture dish (U40 magni¢cation). B: Treatment of the
HIMEC with 2.5 mM sodium butyrate inhibits formation of micro-
vascular tubes following overnight incubation (U40 magni¢cation).
C: PGI2 analog carbacyclin partially restores endothelial tube for-
mation in the sodium butyrate-treated HIMEC (U40 magni¢cation).
D: Quanti¢cation of Matrigel1 in vitro tube formation assay using
overnight HIMEC culture. At least 10 high-power ¢elds per condi-
tion were examined and experiments were repeated in three indepen-
dent HIMEC cultures. Data were expressed as a mean number of
tubes per high-power ¢eld (U200)I S.D. Tube formation was inhib-
ited by sodium butyrate and was signi¢cantly reversed by exogenous
carbacyclin administration. *=P6 0.05 compared to HIMEC
treated with sodium butyrate without PG administration (lane 2) by
ANOVA.
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modulation of pathways including tumor suppressor genes
and altering VEGF receptor expression [20,21]. Our experi-
ments in HIMEC have con¢rmed that sodium butyrate’s
modulatory e¡ect on gene expression is similar to the e¡ect
of the HDAC inhibitor tricostatin A [12]. Taken together,
these results suggest that the anti-angiogenic activity of so-
dium butyrate involves modulation of multiple pathways in
endothelial cells.
The importance of enteric bacteria in the development of a
mature intestinal microcirculation was recently identi¢ed by
Stappenbeck et al. [22]. These investigators demonstrated that
intestinal angiogenesis during normal growth was intimately
related to the presence of indigenous enteric microbes, whose
proximity resulted in the production of Paneth cell-derived
antimicrobial peptides which mediated postnatal vascular de-
velopment. Our data demonstrate that the inter-relationship
between enteric £ora and the vasculature is even more com-
plex, as the presence of bacterial fermentation products will
exert potent anti-angiogenic e¡ects on local endothelial pop-
ulations. Although the local concentration of sodium butyrate
within colonic mucosa is unclear, concentrations of butyrate
in the human portal vein reach 0.03 mM after cecal instilla-
tion of lactulose [23] and a recent report showed that approx-
imately half of absorbed butyrate is found in mesenteric blood
as non-metabolized substrate in rats [24]. These reports sug-
gest that mucosal microvascular endothelial cells are exposed
to sodium butyrate in vivo. In addition, plasma levels of bu-
tyrate are reported to reach 0.1^9 mM in rodents by oral
administration of tributyrin or sodium butyrate [25], which
is similar to the butyrate doses used in the present study.
In summary, our present study indicates that sodium buty-
rate is a potent inhibitor of angiogenesis of HIMEC in vitro.
The mechanisms involve inhibition of COX-2 expression and
prostanoid production. Given the importance of angiogenesis
and tumor neovascularization in cancer progression, our data
suggest that the anti-cancer e¡ects of sodium butyrate may
also involve direct e¡ects on local microvascular populations.
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Fig. 5. E¡ect of sodium butyrate on transmigration and in vitro
tube formation of HIMEC. A: Endothelial transmigration assay
was performed with the COX-2-speci¢c inhibitor NS398. The num-
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